<html><body>
null<h2>Case: Test Case1: DM Needs Screening</h2>
57.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">57</td><td width="200">1970-1-1</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-24</td>
<td width="200">Diabetes_Mellitus</td></tr>
<tr> <td width="200"></td>
<td width="200">2010-06-21</td>
<td width="200">PVD</td></tr>
<tr> <td width="200"></td>
<td width="200">2006-02-24</td>
<td width="200">Hypertension</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(57.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No target  or no HbA1C
<p><b>Action Choices</b>
<ul>
<li><b>Lack target or lack HbA1C</b><br>
<ul>
<li><b>Determine goal <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence Target HBA1c</i> evaluate to <b> true</i>)])

<li><b>Order HbA1C <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No HbA1C ever or in past year</i> evaluate to <b> true</b> because <i>null</i>)])
null
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(57.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: unknown[because <i> Eligibility criteria </i> evaluate to <b>unknown</b><i>(eGFR(no value))</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> not on drug therapy
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Recommendation</b>
<ul>
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.()
</ul>
<li><b>Assumption</b>
<ul>
<li>We use the most recent creatinine in the patient's record. If there is no creatinine listed, our recommendations are based on the assumption creatinine is within normal limits.()
<li>We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>not on antihypertensive medication consultation actions</b><br>
<ul>
<li><b>assumption  check presence of creatinine test result <font color=FF0000>preferred</font></b>(rule in criterion<i> absence of creatinine</i> evaluate to <b> true</i>)])
We use the most recent creatinine in the patient's record. If there is no creatinine listed, our recommendations are based on the assumption creatinine is within normal limits.
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> because <i>null</i>)])
We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>no-drug-therapy-choices</b><br>
<ul>
</ul>
</ul>
<h2>Case: Test Case2: DM needs screening</h2>
unknown age, 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2006-08-13</td>
<td width="200">Diabetes-Mellitus-Type1</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: unknown[because <i> Eligibility criteria </i> evaluate to <b>unknown</b><i>(Age(no value))</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No target  or no HbA1C
<p><b>Action Choices</b>
<ul>
<li><b>Lack target or lack HbA1C</b><br>
<ul>
<li><b>Determine goal <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence Target HBA1c</i> evaluate to <b> true</i>)])

<li><b>Order HbA1C <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No HbA1C ever or in past year</i> evaluate to <b> true</b> because <i>null</i>)])
null
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: unknown[because <i> Eligibility criteria </i> evaluate to <b>unknown</b><i>(Age(no value))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Test Case: DM and  Limbthreat</h2>
59.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">59</td><td width="200">1970-1-1</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Systemic infection</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(59.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
<li><b>Presence of limb threatening scenario <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Limb threatening conditions data collected</i> evaluate to <b> true</b> because <i>Systemic infection(yes compared to yes)</i>)])
Refer to appropriate level of care for evaluation and treatment.
</ul>
<li><b>General Rec</b><br>
<ul>
<li><b>General recs <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Confirm follow-up by foot care specialist if indicated and compliance by patient.
All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus. Document.
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No target  or no HbA1C
<p><b>Action Choices</b>
<ul>
<li><b>Lack target or lack HbA1C</b><br>
<ul>
<li><b>Determine goal <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence Target HBA1c</i> evaluate to <b> true</i>)])

<li><b>Order HbA1C <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No HbA1C ever or in past year</i> evaluate to <b> true</b> because <i>null</i>)])
null
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(59.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Test Case: DM and Ischemia/rest pain</h2>
59.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">59</td><td width="200">1970-1-1</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Acute ischemia/rest pain</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(59.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
<li><b>Presence of limb threatening scenario <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Limb threatening conditions data collected</i> evaluate to <b> true</b> because <i>Acute ischemia/rest pain(yes compared to yes)</i>)])
Refer to appropriate level of care for evaluation and treatment.
</ul>
<li><b>General Rec</b><br>
<ul>
<li><b>General recs <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Confirm follow-up by foot care specialist if indicated and compliance by patient.
All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus. Document.
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No target  or no HbA1C
<p><b>Action Choices</b>
<ul>
<li><b>Lack target or lack HbA1C</b><br>
<ul>
<li><b>Determine goal <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence Target HBA1c</i> evaluate to <b> true</i>)])

<li><b>Order HbA1C <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No HbA1C ever or in past year</i> evaluate to <b> true</b> because <i>null</i>)])
null
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(59.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Test Case:DM and High risk foot</h2>
35.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">35</td><td width="200">1970-1-1</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Foot deformities</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(35.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
<li><b>High risk for a foot problem (E) <font color=FF0000>preferred</font></b>(strict rule-in condition<i> High risk for a foot problem</i> evaluate to <b> true</b> because <i>null</i>)])
null
null
</ul>
<li><b>General Rec</b><br>
<ul>
<li><b>General recs <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Confirm follow-up by foot care specialist if indicated and compliance by patient.
All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus. Document.
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No target  or no HbA1C
<p><b>Action Choices</b>
<ul>
<li><b>Lack target or lack HbA1C</b><br>
<ul>
<li><b>Determine goal <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence Target HBA1c</i> evaluate to <b> true</i>)])

<li><b>Order HbA1C <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No HbA1C ever or in past year</i> evaluate to <b> true</b> because <i>null</i>)])
null
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(35.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Test Case: DM Minor lesion 4 weeks ago</h2>
85.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Overall_ADL</td><td width="200">6.0</td><td width="200">2008-2-3</td></tr>
<tr><td width="200">Age</td><td width="200">85</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Average_Pain_in_Last_Week</td><td width="200">8.0</td><td width="200">2008-2-3</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-04</td>
<td width="200">Febijuana UDS</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">minor lesion</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Cardiovascular disease, unspecified</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Angina</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Myocardial_Infarction</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Atrial_Tachycardia</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Heart_Failure</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Pacemaker</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Rheumatic_Disease_Complicated_by_Heart_Failure</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">PVD</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Coronary_Artery_Disease</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Cardiomyopathy</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-05</td>
<td width="200">Amphetamines UDS</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Minor lesion diagnosed ~4weeks ago</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Heart_Block_2nd_Or_3rd_Degree</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Cardiomegaly</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Hypertension_Complicated_by_Heart_Failure</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Hypertension</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(85.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
<li><b>Low risk with minor wound <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Minor wound/lesion YES</i> evaluate to <b> true</b> because <i>minor lesion(yes compared to yes)</i>)])
	Provide local wound care: cleanse wound with saline, remove necrotic and callus tissue, apply appropriate dressing, and other indicated treatments.
	Offload pressure and weight, as indicated: consider lesion site and then provide pressure relief (e.g., special shoes and insoles and bed rest). To avoid further trauma to the lesion site, use a post-operative shoe, offloading, or depressurization footwear based on the lesion site(s).
	Follow-up on a specified schedule: VA facility specific patients with active lesions need to be followed at least monthly.
	Review the Self-Management and Education Module (Module S): reinforce nutrition, exercise and diabetes self-management. Avoid initiation of a calorie restriction diet for weight loss in patients with foot lesions.
	Provide patient and family education.
	Refer for foot care assistance, as needed, for patients unable to carry-out local wound care. Educate a family member on local wound care or refer the patient to a home health service.

</ul>
<li><b>General Rec</b><br>
<ul>
<li><b>General recs <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Confirm follow-up by foot care specialist if indicated and compliance by patient.
All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus. Document.
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No target  or no HbA1C
<p><b>Action Choices</b>
<ul>
<li><b>Lack target or lack HbA1C</b><br>
<ul>
<li><b>Determine goal <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence Target HBA1c</i> evaluate to <b> true</i>)])

<li><b>Order HbA1C <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No HbA1C ever or in past year</i> evaluate to <b> true</b> because <i>null</i>)])
null
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(85.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class II a</b>
<ul>
<li>Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)()
</ul>
<li><b>Class I</b>
<ul>
<li>Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)()
<li>Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)()
<li>Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).()
</ul>
<li><b>Class III</b>
<ul>
<li>Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage C HF</b><br>
<ul>
</ul>
<li><b> </b><br>
<ul>
<li><b>General Recommendations <font color=FF0000>preferred</font></b>(strict rule-in condition<i> HF ICD9 code OR( signs and structural abnormality)</i> evaluate to <b> true</b> because <i>null</i>)])
Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)
Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)

Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)
<li><b>Referrals <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])
Class I
<li><b>Stage B HF action <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>aldosterone antagonist
<ul>
<li>Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who CAN BE CAREFULLY MONITORED for PRESERVED RENAL FUNCTION and NORMAL POTASSIUM concentration. Creatinine should be 2.5 mg per dL or less in men or 2.0 mg per dL or less in women and potassium should be less than 5.0 mEq per liter. Under circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone anatgonists.
<li>preference: preferred
</ul>
<li>hydralazine and nitrates
<ul>
<li>Recommend starting with hydralazine 25mg tid and nitrates 10mg tid. Would not go much above hydralazine 50mg tid and nitrates 40mg tid. Titrate after a month. Beta blockers can avoid the tachycardia caused by hydralazine and nitrates.
<li>preference: preferred
</ul>
<li>Beta blocker for stage C heart failure
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>Beta blocker Stage C with MI
<ul>
<li>preference: preferred
<li>No comment
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction) </font>
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>digoxin
<ul>
<li>Initial recommended dose of digoxin is 0.125mcg daily (or every other day).
<li>parameterized message: dig dose if age>70, egfr<30 or lean body mass
<li>Digitalis can be beneficial in patients with current or prior symptoms of HF and reduced LVEF to decrease hospitalizations for HF (Level of Evidence: B).  ADD ADDL INFO from HF experts to help guide choice of when to add dig
<li>preference: preferred
</ul>
<li>Beta blocker stage B post MI
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>Beta Blocker Stage B no MI
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>NDHP CCB
<ul>
<li>Contraindications:  Heart_Failure(Hypertension_Complicated_by_Heart_Failure, Cardiomyopathy, Cardiomegaly, Rheumatic_Disease_Complicated_by_Heart_Failure, Heart_Failure)  Myocardial_Infarction(Myocardial_Infarction) 
<li>preference: ruled out
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: unknown[because <i> Eligibility criteria </i> evaluate to <b>unknown</b><i>(eGFR(no value))</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<h2>Case: Test Case: DM wound not healed 4weeks (Feb 28 2008)</h2>
43.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Overall_ADL</td><td width="200">5.0</td><td width="200">2008-7-3</td></tr>
<tr><td width="200">Age</td><td width="200">43</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Creatinine</td><td width="200">2.7</td><td width="200">2008-1-21</td></tr>
<tr><td width="200">Average_Pain_in_Last_Week</td><td width="200">7.0</td><td width="200">2008-7-3</td></tr>
<tr><td width="200">ZipCode</td><td width="200">94706.0</td><td width="200">1970-1-1</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-28</td>
<td width="200">minor lesion</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-05-31</td>
<td width="200">Syndrome</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(43.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
<li><b>Low risk no minor wound <font color=FF0000>preferred</font></b>(strict rule-in condition<i> NO Minor wound data collected</i> evaluate to <b> true</b> because <i>minor lesion(0.0 compared to yes)</i>)])
</ul>
<li><b>General Rec</b><br>
<ul>
<li><b>General recs <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Confirm follow-up by foot care specialist if indicated and compliance by patient.
All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus. Document.
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No target  or no HbA1C
<p><b>Action Choices</b>
<ul>
<li><b>Lack target or lack HbA1C</b><br>
<ul>
<li><b>Determine goal <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence Target HBA1c</i> evaluate to <b> true</i>)])

<li><b>Order HbA1C <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No HbA1C ever or in past year</i> evaluate to <b> true</b> because <i>null</i>)])
null
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(43.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Test Case: DM and circulatory symptoms</h2>
93.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Overall_ADL</td><td width="200">4.0</td><td width="200">2008-8-30</td></tr>
<tr><td width="200">Age</td><td width="200">93</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">CREATININE</td><td width="200">1.6</td><td width="200">2005-12-31</td></tr>
<tr><td width="200">Average_Pain_in_Last_Week</td><td width="200">7.0</td><td width="200">2008-8-30</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-13</td>
<td width="200">BENIGN HYPERTENSION</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-13</td>
<td width="200">HYPERPLASIA OF PROSTATE</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-13</td>
<td width="200">circulatory symptoms that limit patients lifestyle</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-13</td>
<td width="200">POSTHERPES TRIGEM NEURAL</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-22</td>
<td width="200">HERED SENSORY NEUROPATHY</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-13</td>
<td width="200">Peripheral Neuropathy</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-13</td>
<td width="200">MONONEURITIS NOS</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-13</td>
<td width="200">HEADACHE</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-13</td>
<td width="200">HYPERLIPIDEMIA NEC/NOS</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(93.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
<li><b>circulatory symptoms that limit patient's  lifestyle <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of circulatory symptoms that limit patient's lifestyle</i> evaluate to <b> true</i>)])
null
</ul>
<li><b>General Rec</b><br>
<ul>
<li><b>General recs <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Confirm follow-up by foot care specialist if indicated and compliance by patient.
All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus. Document.
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No target  or no HbA1C
<p><b>Action Choices</b>
<ul>
<li><b>Lack target or lack HbA1C</b><br>
<ul>
<li><b>Determine goal <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence Target HBA1c</i> evaluate to <b> true</i>)])

<li><b>Order HbA1C <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No HbA1C ever or in past year</i> evaluate to <b> true</b> because <i>null</i>)])
null
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(93.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Test Case: DM and Hammer Toe</h2>
70.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">70</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.1</td><td width="200">2008-7-11</td></tr>
<tr><td width="200">HbA1C</td><td width="200">7</td><td width="200">2008-7-11</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">8.0</td><td width="200">2008-7-11</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">Ingrown toenail</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">hammer toes</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">Acute ischemia or rest pain</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">Systemic infection</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">Puncture wound</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Atrial_Tachycardia</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">Hemorrhagic callus with or without cellulitis</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-15</td>
<td width="200">Sex</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(70.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
<li><b>Presence of limb threatening scenario <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Limb threatening conditions data collected</i> evaluate to <b> true</b> because <i>null</i>)])
Refer to appropriate level of care for evaluation and treatment.
</ul>
<li><b>General Rec</b><br>
<ul>
<li><b>General recs <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Confirm follow-up by foot care specialist if indicated and compliance by patient.
All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus. Document.
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Nonpharmacologic Therapy
<p>
<b>Goal:</b> HBA1C <= target(presence of target HBA1C)
<p><b>Reached goal?</b> achieved(HbA1C(6.7/2008-7-11; target:8.0))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>Consider aspirin therapy to reduce the risk of cardiovascular fatal events.()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Nonpharmacologic therapy</b><br>
<ul>
<li><b>Start aspirin <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Consider aspirin therapy to reduce the risk of cardiovascular fatal events.
</ul>
<li><b>DM - No meds</b><br>
<ul>
<li><b>Is patient high risk? If yes, refer <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

null
<li><b>HbA1C controlled <font color=FF0000>preferred</font></b>(strict rule-in condition<i> HBA1C <= target</i> evaluate to <b> true</b> because <i>HbA1C(6.7/2008-7-11; target:8.0)</i>)])
Latest HbA1c under control.  Continue therapy and periodically reevaluate appropriateness of target.
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(70.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
<li>Ventricular rate should be controlled or sinus rhythm restored in
patients with supraventricular tachyarrhythmias who are at high
risk for developing HF. (Level of Evidence: B)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>Ventricular rate/sinus rhythm  control <font color=FF0000>preferred</font></b>(rule in criterion<i> Presence of supraventricular tachyarrhythmias</i> evaluate to <b> true</i>)])
Ventricular rate should be controlled or sinus rhythm restored in
patients with supraventricular tachyarrhythmias who are at high
risk for developing HF. (Level of Evidence: B)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Test Case: DM and Loss of sensation</h2>
82.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">82</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.2</td><td width="200">2007-7-11</td></tr>
<tr><td width="200">HbA1C</td><td width="200">8</td><td width="200">2007-7-11</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">105</td><td width="200">2007-7-11</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">35</td><td width="200">2007-7-11</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">200</td><td width="200">2007-7-11</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">8.0</td><td width="200">2008-7-11</td></tr>
</table>
<p><b>Medications:</b> GLIMEPIRIDE(0.0) METFORMIN(0.0) PIOGLITAZONE(0.0) 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">Ingrown toenail</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">hammer toes</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">Acute ischemia or rest pain</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">Puncture wound</td></tr>
<tr> <td width="200"></td>
<td width="200">2007-07-11</td>
<td width="200">UrineProtein_Qualitative</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Atrial_Tachycardia</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">Hemorrhagic callus with or without cellulitis</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">Lack of sensation to Semmes-Weinstein 5.07 monofilament yes/no</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-15</td>
<td width="200">Sex</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(82.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
<li><b>High risk for a foot problem (E) <font color=FF0000>preferred</font></b>(strict rule-in condition<i> High risk for a foot problem</i> evaluate to <b> true</b> because <i>null</i>)])
null
null
</ul>
<li><b>General Rec</b><br>
<ul>
<li><b>General recs <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Confirm follow-up by foot care specialist if indicated and compliance by patient.
All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus. Document.
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Combination therapy w/ oral agents
<p>
<b>Goal:</b> HBA1C <= target(presence of target HBA1C)
<p><b>Reached goal?</b> failed(HbA1C(8.2/2007-7-11; target:8.0))
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>On meds</b><br>
<ul>
<li><b>Metformin check serum B12 <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of biguanide</i> evaluate to <b> true</i>)])
<li><b>Add ACE message <font color=FF0000>preferred</font></b>(rule in criterion<i> Absence of ACE Inhibitor</i> evaluate to <b> true</i>)])
Many DM practitioners add ACE inhibitors to patients regimen regardless of kidney function.
</ul>
<li><b>DM - Oral Agent(s)</b><br>
<ul>
<li><b>Is patient high risk? If yes, refer <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

null
<li><b>Intensify drug treatment <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Goal not satisfied</i> evaluate to <b> true</b> because <i>Goal not satisfiedHbA1C(8.2/2007-7-11; target:8.0)</i>)])
</ul>
<li><b>Intensify choices</b><br>
<ul>
<li><b>Add insulin <font color=FF0000>preferred</font></b>(strict rule-in condition<i> HbA1C > Target_HbA1c</i> evaluate to <b> true</b> because <i>HbA1C(8.2/2007-7-11; target:8.0)</i>)])

<li><b>Increase dose <font color=FF0000>preferred</font></b>(strict rule-in condition<i> there exists non-contraindicated meds not at max level</i> evaluate to <b> true</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Insulin
<ul>
<li>Bad drug partner:  SULFONYLUREAS(GLIMEPIRIDE) 
<li><font color=FF0000>Compelling indications:  Diabetes_Mellitus(Diabetes_Mellitus) </font>
<li>Staring insulin therapy requires closer monitoring by patient and clinician, has a higher risk of hypoglycemic events and requires injections.
<li>preference: ruled out
</ul>
</ul>
<b>If changing attribute, consider: </b><ul>
<li>METFORMIN(change daily_dose: up to High_Dose(high/low))

</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(82.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> failed(LDL_Cholesterol(105.0/2007-7-11))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> failed(LDL_Cholesterol(105.0/2007-7-11))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)()
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
<li>Ventricular rate should be controlled or sinus rhythm restored in
patients with supraventricular tachyarrhythmias who are at high
risk for developing HF. (Level of Evidence: B)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>Lipid disorder control <font color=FF0000>preferred</font></b>(rule in criterion<i> Lipid not under control</i> evaluate to <b> true</b> because <i>Lipid not under controlLDL_Cholesterol(105.0/2007-7-11)</i>)])
In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>Ventricular rate/sinus rhythm  control <font color=FF0000>preferred</font></b>(rule in criterion<i> Presence of supraventricular tachyarrhythmias</i> evaluate to <b> true</i>)])
Ventricular rate should be controlled or sinus rhythm restored in
patients with supraventricular tachyarrhythmias who are at high
risk for developing HF. (Level of Evidence: B)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Test Case:DM with metformin 2300 and sulfonylurea 300</h2>
75.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">75</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.8</td><td width="200">2008-10-23</td></tr>
<tr><td width="200">HbA1C</td><td width="200">10</td><td width="200">2008-7-11</td></tr>
<tr><td width="200">Microalbumin/Creatinine Ratio</td><td width="200">35</td><td width="200">2008-8-23</td></tr>
<tr><td width="200"></td><td width="200">40</td><td width="200">2008-10-23</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">180</td><td width="200">2008-10-23</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">8.0</td><td width="200">2008-7-11</td></tr>
</table>
<p><b>Medications:</b> METFORMIN(0.0) SULFONYLUREAS(0.0) 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">Race</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-10-23</td>
<td width="200">Lack of sensation to Semmes-Weinstein 5.07 monofilament at one or more noncallused plantar sites</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-10-23</td>
<td width="200">Acute ocular changes</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-10-17</td>
<td width="200">DM-Type2</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">Sex</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(75.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Urgent referral eye provider <font color=FF0000>preferred</font></b>(strict rule-in condition<i> acute vision change or change ocular function</i> evaluate to <b> true</b> because <i>null</i>)])
null
Patient has an acute vision change.  Please refer to an opthamologist immediately.
In CPRS go here..., and do it now.
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
<li><b>High risk for a foot problem (E) <font color=FF0000>preferred</font></b>(strict rule-in condition<i> High risk for a foot problem</i> evaluate to <b> true</b> because <i>null</i>)])
null
null
</ul>
<li><b>General Rec</b><br>
<ul>
<li><b>General recs <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Confirm follow-up by foot care specialist if indicated and compliance by patient.
All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus. Document.
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
<li>Creatinine > 1.5 and Male: [because <i> Creatinine > 1.5 and Male </i> evaluate to <b>true</b><i>(Creatinine(1.8/2008-10-23) && Sex(Male compared to Male))</i>]
</ul>
<b>Scenario choice:</b> Combination therapy w/ oral agents
<p>
<b>Goal:</b> HBA1C <= target(presence of target HBA1C)
<p><b>Reached goal?</b> failed(HbA1C(10.0/2008-7-11; target:8.0))
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>On meds</b><br>
<ul>
<li><b>Metformin check serum B12 <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of biguanide</i> evaluate to <b> true</i>)])
<li><b>Add ACE message <font color=FF0000>preferred</font></b>(rule in criterion<i> Absence of ACE Inhibitor</i> evaluate to <b> true</i>)])
Many DM practitioners add ACE inhibitors to patients regimen regardless of kidney function.
</ul>
<li><b>DM - Oral Agent(s)</b><br>
<ul>
<li><b>Is patient high risk? If yes, refer <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

null
<li><b>Substitute <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of contraindication</i> evaluate to <b> true</i>)])

<li><b>Intensify drug treatment <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Goal not satisfied</i> evaluate to <b> true</b> because <i>Goal not satisfiedHbA1C(10.0/2008-7-11; target:8.0)</i>)])
</ul>
<li><b>Intensify choices</b><br>
<ul>
</ul>
</ul>
<b>Considerations for substituting drug: </b><ul>
<li> Substitution: replace 
<ul>
<li>METFORMIN(BIGUANIDE)
<ul>
<li>Compelling indications:  DM-Type2(DM-Type2) 
<li>Contraindications:  Creatinine > 1.5 and Male(Creatinine > 1.5 and Male[Creatinine(1.8/2008-10-23) && Sex(Male compared to Male)]) 
</ul>
 with <li>DIPEPTIDYL_PEPTIDASE-4_INHIBITOR
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>MEGLITINIDES
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>Sulfonylureas 1st generation
<ul>
<li>	Efficacy ( HbA1c) a = 1.0 - 2.0 %
	1st generation sulfonylureas are no longer commonly used.
	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
	The preferred agents have shorter half-lives and inactive metabolites.
	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
	Inexpensive
<li>preference: preferred
</ul>
<li>THIAZOLIDINEDIONES
<ul>
<li>Thiazolidinediones are less effective in lowering HbA1C, have a higher cost, and are non formulary.
<li>Check liver enzymes every 2-3 months during first year of thiazolidinedione therapy to evaluate for potential hepatitis.
<li>preference: preferred
</ul>
<li>GLIPIZIDE
<ul>
<li>Relative indications:  DM-Type2(DM-Type2) 
<li>	Efficacy ( HbA1c) a = 1.0 - 2.0 %
	1st generation sulfonylureas are no longer commonly used.
	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
	The preferred agents have shorter half-lives and inactive metabolites.
	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
	Inexpensive
<li>preference: preferred
</ul>
<li>GLYBURIDE
<ul>
<li>Bad drug partner:  SULFONYLUREAS(SULFONYLUREAS) 
<li>	Efficacy ( HbA1c) a = 1.0 - 2.0 %
	1st generation sulfonylureas are no longer commonly used.
	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
	The preferred agents have shorter half-lives and inactive metabolites.
	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
	Inexpensive
<li>preference: ruled out
</ul>
</ul>

</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(75.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> failed(LDL_Cholesterol(180.0/2008-10-23))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Initiate lipid lowering drug therapy and therapeutic lifestyle changes</font>()
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>LDL>=130, Initiate Drug Therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> (CHD or CHD equivalent) and LDL>=130</i> evaluate to <b> true</b> because <i>null && LDL_Cholesterol(180.0/2008-10-23)</i>)])
<b><font color=red>Initiate lipid lowering drug therapy and therapeutic lifestyle changes</font>

<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Bile_Acid_Sequestrant
<ul>
<li>Relative indications:  LDL_not_within_guideline_goal(LDL not within guideline goal[Not within guideline goalLDL_Cholesterol(180.0/2008-10-23)]) 
<li>Warning:  This lipid lowering drug may increase TG levels.
<li>preference: preferred
</ul>
<li>Nicotinic Acid
<ul>
<li>Relative indications:  LDL_not_within_guideline_goal(LDL not within guideline goal[Not within guideline goalLDL_Cholesterol(180.0/2008-10-23)]) 
<li>Relative contraindications:  Diabetes_Mellitus(DM-Type2) 
<li>Potential adverse effects of niacin include hepatotoxicity, hyperglycemia, hyperuricemia
<li>preference: preferred
</ul>
<li>Fibric Acid
<ul>
<li>Recommend monitoring LFTs throughout therapy.
<li>Potential adverse effects of fibreates include:  hepatitis, gallstones, myalgia, and myopathy and rhabdomyolysis.
Risk of myopathy/rhabdomyolysis increases when combined with statins.
<li>preference: preferred
</ul>
<li>Cholesterol Absorption Inhibitors
<ul>
<li>preference: preferred
<li>No comment
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> failed(LDL_Cholesterol(180.0/2008-10-23))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)()
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>Lipid disorder control <font color=FF0000>preferred</font></b>(rule in criterion<i> Lipid not under control</i> evaluate to <b> true</b> because <i>Lipid not under controlLDL_Cholesterol(180.0/2008-10-23)</i>)])
In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Test Case: DM and insulin</h2>
46.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">46</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Fraction_Missed_Appointments</td><td width="200">0.4</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">HbA1C</td><td width="200">9</td><td width="200">2008-7-11</td></tr>
<tr><td width="200">Num_Appointments</td><td width="200">23.0</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">ZipCode</td><td width="200">94012.0</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">8.0</td><td width="200">2008-7-11</td></tr>
</table>
<p><b>Medications:</b> Insulin(0.0) 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(46.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Insulin therapy only
<p>
<b>Goal:</b> HBA1C <= target(presence of target HBA1C)
<p><b>Reached goal?</b> failed(HbA1C(9.0/2008-7-11; target:8.0))
<p><b>Action Choices</b>
<ul>
<li><b>DM -  Insulin only</b><br>
<ul>
<li><b>Is patient high risk? If yes, refer <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

null
<li><b>Add metformin <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Goal not satisfied</i> evaluate to <b> true</b> because <i>Goal not satisfiedHbA1C(9.0/2008-7-11; target:8.0)</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Biguanide
<ul>
<li>Withhold metformin in the presence of any condition associated with hipoxemia, dehydration or sepsis.
<li>	Efficacy ( HbA1c) a 1.0 - 2.0%
	The major blood glucose lowering effect is through decreasing hepatic glucose                           production with some decrease in peripheral insulin resistance 
	May restore ovulation in premenopausal anovulatory females.
	Monitor renal function prior to drug initiation and at least annually thereafter.
	Inexpensive when using generic.
<li>Check B12 levels every 2 years when a patient is using Metformin.
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(46.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Test Case: DM and no drugs</h2>
62.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">62</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Creatinine</td><td width="200">2.0</td><td width="200">2008-7-15</td></tr>
<tr><td width="200">HbA1C</td><td width="200">9</td><td width="200">2008-7-11</td></tr>
<tr><td width="200">BMI</td><td width="200">28</td><td width="200">2008-7-11</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">8.0</td><td width="200">2008-6-1</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-15</td>
<td width="200">Sex</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(62.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
<li>Overweight (25<BMI<29): [because <i> 25<BMI<29 </i> evaluate to <b>true</b><i>(BMI(28.0/2008-7-11) && BMI(28.0/2008-7-11))</i>]
<li>Creatinine > 1.5 and Male: [because <i> Creatinine > 1.5 and Male </i> evaluate to <b>true</b><i>(Creatinine(2.0/2008-7-15) && Sex(Male compared to Male))</i>]
</ul>
<b>Scenario choice:</b> Nonpharmacologic Therapy
<p>
<b>Goal:</b> HBA1C <= target(presence of target HBA1C)
<p><b>Reached goal?</b> failed(HbA1C(9.0/2008-7-11; target:8.0))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>Consider aspirin therapy to reduce the risk of cardiovascular fatal events.()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Nonpharmacologic therapy</b><br>
<ul>
<li><b>Start aspirin <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Consider aspirin therapy to reduce the risk of cardiovascular fatal events.
</ul>
<li><b>DM - No meds</b><br>
<ul>
<li><b>Is patient high risk? If yes, refer <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

null
<li><b>Metformin contraindicated, add Glipizide <font color=FF0000>preferred</font></b>(strict rule-in condition<i> HbA1C > Target_HbA1c</i> evaluate to <b> true</b> because <i>HbA1C(9.0/2008-7-11; target:8.0)</i>)])
Add Glipizide
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>GLIPIZIDE
<ul>
<li>	Efficacy ( HbA1c) a = 1.0 - 2.0 %
	1st generation sulfonylureas are no longer commonly used.
	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
	The preferred agents have shorter half-lives and inactive metabolites.
	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
	Inexpensive
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(62.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Test case: DM and metformin 2300</h2>
59.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">59</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Creatinine</td><td width="200">2.0</td><td width="200">2009-12-7</td></tr>
<tr><td width="200">HbA1C</td><td width="200">9</td><td width="200">2009-7-11</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">130</td><td width="200">2008-10-16</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">8.0</td><td width="200">2009-7-11</td></tr>
</table>
<p><b>Medications:</b> METFORMIN(0.0) 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2008-10-23</td>
<td width="200">hammer toes</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-10-16</td>
<td width="200">Ingrown toenail</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-10-16</td>
<td width="200">change in ocular function</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-10-16</td>
<td width="200">Dorsalis pedis pulses</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-10-17</td>
<td width="200">DM-Type2</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">Sex</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(59.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Urgent referral eye provider <font color=FF0000>preferred</font></b>(strict rule-in condition<i> acute vision change or change ocular function</i> evaluate to <b> true</b> because <i>null</i>)])
null
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
<li><b>High risk for a foot problem (E) <font color=FF0000>preferred</font></b>(strict rule-in condition<i> High risk for a foot problem</i> evaluate to <b> true</b> because <i>null</i>)])
null
null
</ul>
<li><b>General Rec</b><br>
<ul>
<li><b>General recs <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Confirm follow-up by foot care specialist if indicated and compliance by patient.
All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus. Document.
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
<li>Creatinine > 1.5 and Male: [because <i> Creatinine > 1.5 and Male </i> evaluate to <b>true</b><i>(Creatinine(2.0/2009-12-7) && Sex(Male compared to Male))</i>]
</ul>
<b>Scenario choice:</b> Monotherapy w/ oral agent
<p>
<b>Goal:</b> HBA1C <= target(presence of target HBA1C)
<p><b>Reached goal?</b> failed(HbA1C(9.4/2009-7-11; target:8.0))
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>On meds</b><br>
<ul>
<li><b>Metformin check serum B12 <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of biguanide</i> evaluate to <b> true</i>)])
<li><b>Add ACE message <font color=FF0000>preferred</font></b>(rule in criterion<i> Absence of ACE Inhibitor</i> evaluate to <b> true</i>)])
Many DM practitioners add ACE inhibitors to patients regimen regardless of kidney function.
</ul>
<li><b>DM - Oral Agent(s)</b><br>
<ul>
<li><b>Is patient high risk? If yes, refer <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

null
<li><b>Substitute <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of contraindication</i> evaluate to <b> true</i>)])

<li><b>Intensify drug treatment <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Goal not satisfied</i> evaluate to <b> true</b> because <i>Goal not satisfiedHbA1C(9.4/2009-7-11; target:8.0)</i>)])
</ul>
<li><b>Intensify choices</b><br>
<ul>
</ul>
</ul>
<b>Considerations for substituting drug: </b><ul>
<li> Substitution: replace 
<ul>
<li>METFORMIN(BIGUANIDE)
<ul>
<li>Compelling indications:  DM-Type2(DM-Type2) 
<li>Contraindications:  Creatinine > 1.5 and Male(Creatinine > 1.5 and Male[Creatinine(2.0/2009-12-7) && Sex(Male compared to Male)]) 
</ul>
 with <li>DIPEPTIDYL_PEPTIDASE-4_INHIBITOR
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>MEGLITINIDES
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>Sulfonylureas 1st generation
<ul>
<li>	Efficacy ( HbA1c) a = 1.0 - 2.0 %
	1st generation sulfonylureas are no longer commonly used.
	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
	The preferred agents have shorter half-lives and inactive metabolites.
	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
	Inexpensive
<li>preference: preferred
</ul>
<li>THIAZOLIDINEDIONES
<ul>
<li>Thiazolidinediones are less effective in lowering HbA1C, have a higher cost, and are non formulary.
<li>Check liver enzymes every 2-3 months during first year of thiazolidinedione therapy to evaluate for potential hepatitis.
<li>preference: preferred
</ul>
<li>GLIPIZIDE
<ul>
<li>Relative indications:  DM-Type2(DM-Type2) 
<li>	Efficacy ( HbA1c) a = 1.0 - 2.0 %
	1st generation sulfonylureas are no longer commonly used.
	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
	The preferred agents have shorter half-lives and inactive metabolites.
	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
	Inexpensive
<li>preference: preferred
</ul>
<li>GLYBURIDE
<ul>
<li>	Efficacy ( HbA1c) a = 1.0 - 2.0 %
	1st generation sulfonylureas are no longer commonly used.
	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
	The preferred agents have shorter half-lives and inactive metabolites.
	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
	Inexpensive
<li>preference: preferred
</ul>
</ul>

</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(59.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> failed(LDL_Cholesterol(130.0/2008-10-16))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Initiate lipid lowering drug therapy and therapeutic lifestyle changes</font>()
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>LDL>=130, Initiate Drug Therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> (CHD or CHD equivalent) and LDL>=130</i> evaluate to <b> true</b> because <i>null && LDL_Cholesterol(130.0/2008-10-16)</i>)])
<b><font color=red>Initiate lipid lowering drug therapy and therapeutic lifestyle changes</font>

<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Bile_Acid_Sequestrant
<ul>
<li>Relative indications:  LDL_not_within_guideline_goal(LDL not within guideline goal[Not within guideline goalLDL_Cholesterol(130.0/2008-10-16)]) 
<li>Warning:  This lipid lowering drug may increase TG levels.
<li>preference: preferred
</ul>
<li>Nicotinic Acid
<ul>
<li>Relative indications:  LDL_not_within_guideline_goal(LDL not within guideline goal[Not within guideline goalLDL_Cholesterol(130.0/2008-10-16)]) 
<li>Relative contraindications:  Diabetes_Mellitus(DM-Type2, Diabetes_Mellitus) 
<li>Potential adverse effects of niacin include hepatotoxicity, hyperglycemia, hyperuricemia
<li>preference: preferred
</ul>
<li>Fibric Acid
<ul>
<li>Recommend monitoring LFTs throughout therapy.
<li>Potential adverse effects of fibreates include:  hepatitis, gallstones, myalgia, and myopathy and rhabdomyolysis.
Risk of myopathy/rhabdomyolysis increases when combined with statins.
<li>preference: preferred
</ul>
<li>Cholesterol Absorption Inhibitors
<ul>
<li>preference: preferred
<li>No comment
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> failed(LDL_Cholesterol(130.0/2008-10-16))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)()
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>Lipid disorder control <font color=FF0000>preferred</font></b>(rule in criterion<i> Lipid not under control</i> evaluate to <b> true</b> because <i>Lipid not under controlLDL_Cholesterol(130.0/2008-10-16)</i>)])
In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: Samson Test Patient</h2>
55.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">DB_Diastolic_BP</td><td width="200">95</td><td width="200">2009-2-25</td></tr>
<tr><td width="200">Age</td><td width="200">55</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">HbA1C</td><td width="200">9</td><td width="200">2010-3-11</td></tr>
<tr><td width="200">DB_Systolic_BP</td><td width="200">150</td><td width="200">2009-2-25</td></tr>
<tr><td width="200">ZipCode</td><td width="200">94012.0</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">8.0</td><td width="200">2010-3-11</td></tr>
</table>
<p><b>Medications:</b> lisinopril(0.0) 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-25</td>
<td width="200">Hypertension</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(55.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Nonpharmacologic Therapy
<p>
<b>Goal:</b> HBA1C <= target(presence of target HBA1C)
<p><b>Reached goal?</b> failed(HbA1C(9.0/2010-3-11; target:8.0))
<p><b>Action Choices</b>
<ul>
<li><b>Nonpharmacologic therapy</b><br>
<ul>
</ul>
<li><b>DM - No meds</b><br>
<ul>
<li><b>Is patient high risk? If yes, refer <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

null
<li><b>Add metformin <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Goal not satisfied</i> evaluate to <b> true</b> because <i>Goal not satisfiedHbA1C(9.0/2010-3-11; target:8.0)</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Biguanide
<ul>
<li>Withhold metformin in the presence of any condition associated with hipoxemia, dehydration or sepsis.
<li>	Efficacy ( HbA1c) a 1.0 - 2.0%
	The major blood glucose lowering effect is through decreasing hepatic glucose                           production with some decrease in peripheral insulin resistance 
	May restore ovulation in premenopausal anovulatory females.
	Monitor renal function prior to drug initiation and at least annually thereafter.
	Inexpensive when using generic.
<li>Check B12 levels every 2 years when a patient is using Metformin.
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(55.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> failed(Treatment_Diastolic_BP/null(95))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporary
guidelines. (Level of Evidence: A)()
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>Hypertension control <font color=FF0000>preferred</font></b>(rule in criterion<i> BP not under control</i> evaluate to <b> true</b> because <i>BP not under controlTreatment_Diastolic_BP/null(95)</i>)])
In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporary
guidelines. (Level of Evidence: A)
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
<li>Ace_Inhibitor
<ul>
<li>Already being used
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: ruled out
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: unknown[because <i> Eligibility criteria </i> evaluate to <b>unknown</b><i>(eGFR(no value))</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> on one anti-hypertensive drug
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> failed(Treatment_Diastolic_BP/null(95))
<p><b>Messages by Types</b>
<ul>
<li><b>Recommendation</b>
<ul>
<li>It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: lisinopril()
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.()
<li>There is an allergy or adverse drug reaction reported for a drug that is recommended below. Consult the Patient History for a listing of the reported event and use clinical judgment to determine whether to disgard the recommendation.()
<li>Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.()
</ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.()
</ul>
<li><b>Assumption</b>
<ul>
<li>We use the most recent creatinine in the patient's record. If there is no creatinine listed, our recommendations are based on the assumption creatinine is within normal limits.()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>on medication: things to check</b><br>
<ul>
<li><b>assumption  check presence of creatinine test result <font color=FF0000>preferred</font></b>(rule in criterion<i> absence of creatinine</i> evaluate to <b> true</i>)])
We use the most recent creatinine in the patient's record. If there is no creatinine listed, our recommendations are based on the assumption creatinine is within normal limits.
<li><b>adverse event warning <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of current medication with adverse reaction</i> evaluate to <b> true</i>)])
<li><b>test parameterized message <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: lisinopril
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>one-drug-therapy-choices</b><br>
<ul>
<li><b>Blood pressure not adequately controlled; intensify drug treatment <font color=FF0000>preferred</font></b>(strict rule-in condition<i> BP not adequately controlled based on most recent BP</i> evaluate to <b> true</b> because <i>BP not adequately controlled based on most recent BPTreatment_Diastolic_BP/null(95)</i>)])
Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.
</ul>
<li><b>step up choices</b><br>
<ul>
<li><b>evaluate new drug to prescribe <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

<li><b>Increasing dose <font color=FF0000>preferred</font></b>(strict rule-in condition<i> dose level not at maximum and if taking diuretics, not hypokalemia</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
<li><b>increase dose considerations</b><br>
<ul>
</ul>
<li><b>addition considerations</b><br>
<ul>
<li><b>ADE Recommended Drug <font color=FF0000>preferred</font></b>(rule in criterion<i> ADE for Recommended Drug</i> evaluate to <b> true</i>)])
There is an allergy or adverse drug reaction reported for a drug that is recommended below. Consult the Patient History for a listing of the reported event and use clinical judgment to determine whether to disgard the recommendation.
<li><b>add BB and dislipidemia <font color=FF0000>preferred</font></b>(rule in criterion<i> Beta Blocker Add</i> evaluate to <b> true</i>)])
Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Thiazide Diuretic 
<ul>
<li><font color=FF0000>Compelling indications:  Diabetes_Mellitus(Diabetes_Mellitus) </font>
<li>preference: preferred
</ul>
<li>Cardioselective Beta Blocker 
<ul>
<li>Relative indications:  Diabetes_Mellitus(Diabetes_Mellitus) 
<li>Beta blockers may diminish symptoms of and recovery from hypoglycemia and should be used with caution in patients who are prone to hypoglycemia.
<li>Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li>Diagnoses from EKG reports are not extracted. If patient has an arrythmia that is not shown in patient summary, please update problem list.
<li>preference: preferred
</ul>
<li>DHP Calcium Channel Blocker 
<ul>
<li>Relative indications:  Diabetes_Mellitus(Diabetes_Mellitus) 
<li>preference: preferred
</ul>
<li>(non-DHP) Calcium Channel Blocker 
<ul>
<li>Diagnoses from EKG reports are not extracted. If patient has an arrythmia that is not shown in patient summary, please update problem list.
<li>preference: preferred
</ul>
<li>Potassium Sparing Diuretic 
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>Alpha Blocker 
<ul>
<li>To decrease the likelihood of syncope or excessive hypotension treatment should usually be initiated with a dose of 1 or 2 mgs at bedtime. The dose should be increased in a stepwise fashion. Blood pressures should be measured to check for postural drop.
<li>Compellingly indicated if the patient has symptomatic BPH.
<li>preference: preferred
</ul>
<li>Angiotensin II Receptor Blocker 
<ul>
<li>Bad drug partner:  ACE_Inhibitors(lisinopril) 
<li>Relative indications:  Diabetes_Mellitus(Diabetes_Mellitus) 
<li>Check the patient's plasma creatinine and potassium concentrations when prescribing or increasing dose of  angiotensin II receptor blockers.
<li>preference: ruled out
</ul>
<li>ACE Inhibitor 
<ul>
<li>Already being used
<li><font color=FF0000>Compelling indications:  Diabetes_Mellitus(Diabetes_Mellitus) </font>
<li>This is a test of the references feature.
<li>preference: ruled out
</ul>
</ul>
<h2>Case: Test Case: DM and 1 hypoglycemic agent and insulin</h2>
75.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">75</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">HbA1C</td><td width="200">9</td><td width="200">2008-7-15</td></tr>
<tr><td width="200">ZipCode</td><td width="200">94012.0</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">2008-7-15</td></tr>
</table>
<p><b>Medications:</b> METFORMIN(0.0) Insulin(0.0) 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-24</td>
<td width="200">Last_UDS_Taken</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(75.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Combination oral agents/insulin therapy
<p>
<b>Goal:</b> HBA1C <= target(presence of target HBA1C)
<p><b>Reached goal?</b> failed(HbA1C(9.0/2008-7-15; target:7.0))
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>On meds</b><br>
<ul>
<li><b>Metformin check serum B12 <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of biguanide</i> evaluate to <b> true</i>)])
<li><b>Add ACE message <font color=FF0000>preferred</font></b>(rule in criterion<i> Absence of ACE Inhibitor</i> evaluate to <b> true</i>)])
Many DM practitioners add ACE inhibitors to patients regimen regardless of kidney function.
</ul>
<li><b>DM - Oral agents and insulin</b><br>
<ul>
<li><b>Increase dose <font color=FF0000>preferred</font></b>(strict rule-in condition<i> there exists non-contraindicated meds not at max level</i> evaluate to <b> true</i>)])

<li><b>Is patient high risk? If yes, refer <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

null
</ul>
</ul>
<b>If changing attribute, consider: </b><ul>
<li>METFORMIN(change daily_dose: up to High_Dose(high/low))

</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(75.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2>Case: DM and Last eye exam <1 year ago, refer every year</h2>
unknown age, 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2009-07-01</td>
<td width="200">Presence eye exam in past year</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: unknown[because <i> Eligibility criteria </i> evaluate to <b>unknown</b><i>(Age(no value))</i>]
<li>0-1 Risk Factor: [because <i> Absence of CHD/CHD Equivalent and 0-1 Risk Factors </i> evaluate to <b>true</b><i>(null && 10-Year_CHD_Risk(no value))</i>]
</ul>
<b>Scenario choice:</b> No drug, 0-1 risk factors
<p>
<b>Goal:</b> LDL< 160 mg/dL(0-1 risk factors)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Action Choices</b>
<ul>
<li><b>0-1 risk factor choices</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
</body></html>
